Hepatocellular carcinoma treatment: 4 AGA recommendations

Hepatocellular carcinoma is the most common type of liver cancer, according to Rochester, Minn.-based Mayo Clinic.

The American Gastroenterological Association released guidelines for hepatocellular carcinoma treatment Feb. 22.

Four recommendations from the AGA:

1. Systemic therapies are only recommended for those in stage C with preserved liver function. Atezolizumab and bevacizumab are recommended for first-line treatments rather than sorafenib.

2. Those in stage 0 and A who are also eligible for ablation, resection or transplant should receive curative surgery rather than systemic therapies.

3. Transarterial chemoembolization should be the first-line treatment for those in stage B.

4. Stage D patients should not receive systemic therapies. Instead, they should receive a transplant or best supportive care.

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy.
 

Articles We Think You'll Like